Tirzepatide
Synthetic 39-residue peptide engineered as a dual-agonist of the GIP and GLP-1 receptors; the GIP component appears to augment GLP-1-driven insulin secretion and energy expenditure while modulating appetite via complementary CNS targets.
Tirzepatide is a 39-residue synthetic peptide designed as a balanced dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. A C20 fatty-diacid moiety attached via a γGlu-2×OEG linker drives high-affinity albumin binding and supports once-weekly dosing.
The pharmacology represents a notable shift from earlier mono-agonist programs. GIP and GLP-1 are both incretins, but historically GIP-receptor agonism in obese patients was thought to be physiologically blunted. Tirzepatide’s clinical activity suggests that combined receptor engagement produces additive — and in some endpoints super-additive — effects on glycemic control and body-weight reduction. Mechanistic candidates include complementary CNS appetite circuitry (GIPR is expressed in hypothalamic and brainstem regions distinct from those targeted by GLP-1R), enhanced energy expenditure, and reduced peripheral resistance.
Tirzepatide is approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It remains the subject of active research into cardiometabolic, hepatic (MASH), and inflammatory indications. The molecule is cataloged here for research reference; clinical use requires medical supervision.